Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) shares fell 2.6% on Tuesday . The stock traded as low as $1.43 and last traded at $1.49. 211,045 shares traded hands during mid-day trading, a decline of 56% from the average session volume of 474,548 shares. The stock had previously closed at $1.53.
Tiziana Life Sciences Stock Performance
The firm has a 50 day moving average price of $1.50 and a 200-day moving average price of $1.16.
Institutional Trading of Tiziana Life Sciences
Several institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC increased its holdings in Tiziana Life Sciences by 968.2% in the 1st quarter. Jane Street Group LLC now owns 167,542 shares of the company's stock worth $181,000 after purchasing an additional 151,858 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Tiziana Life Sciences in the first quarter valued at about $25,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Tiziana Life Sciences during the 1st quarter valued at about $156,000. Dauntless Investment Group LLC bought a new stake in shares of Tiziana Life Sciences during the 1st quarter valued at about $1,879,000. Finally, Bison Wealth LLC bought a new position in Tiziana Life Sciences in the fourth quarter worth approximately $30,000.
Tiziana Life Sciences Company Profile
(
Get Free Report)
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
Featured Articles
Before you consider Tiziana Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.
While Tiziana Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
